Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Prime Medicine (PRME) Financials

Prime Medicine logo
$3.08 +0.13 (+4.24%)
As of 01:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Prime Medicine

Annual Income Statements for Prime Medicine

This table shows Prime Medicine's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.06 -184 -142 -198 -196 -201
Consolidated Net Income / (Loss)		 -3.41 -165 -122 -198 -196 -201
Net Income / (Loss) Continuing Operations		 -3.41 -165 -122 -198 -196 -201
Total Pre-Tax Income 		-1.54 -166 -123 -198 -196 -201
Total Operating Income		 -0.93 -84 -117 -205 -202 -208
Total Gross Profit		 5.21 0.00 0.00 0.00 2.98 4.63
Total Revenue		 5.21 0.00 0.00 0.00 2.98 4.63
Operating Revenue		 5.21 0.00 - 0.00 2.98 4.63
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 6.14 84 117 205 205 213
Selling, General & Admin Expense		 3.16 14 30 43 50 52
Research & Development Expense		 2.98 71 87 148 155 161
Total Other Income / (Expense), net		 -0.61 -81 -6.23 6.38 6.59 7.21
Interest & Investment Income		 - - - 2.81 3.52 4.15
Other Income / (Expense), net		 -0.61 -81 -6.23 3.57 3.06 3.06
Basic Earnings per Share		 ($1.91) ($14.19) ($4.19) ($2.18) ($1.65) ($1.35)
Weighted Average Basic Shares Outstanding		 2.64M 12.97M 33.89M 90.97M 118.60M 148.76M
Diluted Earnings per Share		 ($1.91) ($14.19) ($4.19) ($2.18) ($1.65) ($1.35)
Weighted Average Diluted Shares Outstanding		 2.64M 12.97M 33.89M 90.97M 118.60M 148.76M
Weighted Average Basic & Diluted Shares Outstanding		 - - 97.25M 119.94M 131.16M 180.55M

Quarterly Income Statements for Prime Medicine

This table shows Prime Medicine's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -42 -51 -66 -46 -55 -53 -42 -52 -53 -51 -46
Consolidated Net Income / (Loss)		 -42 -51 -66 -46 -55 -53 -42 -52 -53 -51 -46
Net Income / (Loss) Continuing Operations		 -42 -51 -66 -46 -55 -53 -42 -52 -53 -51 -46
Total Pre-Tax Income 		-42 -51 -66 -46 -55 -53 -42 -52 -53 -51 -46
Total Operating Income		 -45 -51 -68 -48 -56 -54 -44 -52 -53 -54 -49
Total Gross Profit		 0.00 0.00 - 0.59 0.00 0.21 2.18 1.45 1.12 1.23 0.84
Total Revenue		 0.00 0.00 - 0.59 0.00 0.21 2.18 1.45 1.12 1.23 0.84
Operating Revenue		 0.00 0.00 - 0.59 0.00 0.21 2.18 1.45 1.12 1.23 0.84
Total Operating Expenses		 45 51 68 49 56 54 46 54 54 55 49
Selling, General & Admin Expense		 11 10 13 11 13 14 12 13 13 11 15
Research & Development Expense		 35 41 41 38 43 40 34 41 41 44 35
Total Other Income / (Expense), net		 2.90 0.64 2.40 2.71 0.21 1.71 1.95 0.50 0.79 3.39 2.53
Interest & Investment Income		 0.64 0.41 - 0.68 0.61 0.70 - 1.18 0.74 1.14 1.08
Other Income / (Expense), net		 2.27 0.23 0.63 2.04 -0.40 1.02 -0.27 -0.68 0.04 2.25 1.45
Basic Earnings per Share		 ($0.47) ($0.55) ($0.72) ($0.44) ($0.46) ($0.44) ($0.31) ($0.40) ($0.41) ($0.32) ($0.22)
Weighted Average Basic Shares Outstanding		 90.47M 91.85M 90.97M 104.47M 119.19M 119.76M 118.60M 130.88M 129.19M 160.50M 148.76M
Diluted Earnings per Share		 ($0.47) ($0.55) ($0.72) ($0.44) ($0.46) ($0.44) ($0.31) ($0.40) ($0.41) ($0.32) ($0.22)
Weighted Average Diluted Shares Outstanding		 90.47M 91.85M 90.97M 104.47M 119.19M 119.76M 118.60M 130.88M 129.19M 160.50M 148.76M
Weighted Average Basic & Diluted Shares Outstanding		 97.30M 97.32M 119.94M 120.03M 120.03M 131.16M 131.16M 131.29M 134.57M 180.51M 180.55M

Annual Cash Flow Statements for Prime Medicine

This table details how cash moves in and out of Prime Medicine's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 28 162 2.57 -146 141 -120
Net Cash From Operating Activities		 -5.54 -34 -132 -165 -123 -163
Net Cash From Continuing Operating Activities		 -5.54 -34 -132 -165 -123 -163
Net Income / (Loss) Continuing Operations		 -3.41 -165 -122 -198 -196 -201
Consolidated Net Income / (Loss)		 -3.41 -165 -122 -198 -196 -201
Depreciation Expense		 0.04 0.57 2.22 4.65 6.13 7.32
Amortization Expense		 0.00 0.72 -0.25 -3.41 -3.09 -1.94
Non-Cash Adjustments To Reconcile Net Income		 -4.21 99 24 43 25 39
Changes in Operating Assets and Liabilities, net		 2.03 31 -36 -11 45 -5.34
Net Cash From Investing Activities		 -1.06 -74 -47 19 68 -109
Net Cash From Continuing Investing Activities		 -1.06 -74 -47 19 68 -109
Purchase of Property, Plant & Equipment		 -0.64 -4.15 -16 -8.72 -7.29 -4.53
Purchase of Investments		 0.00 -82 -123 -105 -129 -205
Sale and/or Maturity of Investments		 0.00 13 93 133 204 101
Other Investing Activities, net		 -0.42 -0.50 -0.67 -0.17 1.00 0.00
Net Cash From Financing Activities		 35 269 181 0.66 196 152
Net Cash From Continuing Financing Activities		 35 269 181 0.66 196 152
Issuance of Debt		 - - - 0.00 132 138
Issuance of Common Equity		 0.00 0.00 185 0.00 58 0.34
Other Financing Activities, net		 0.00 0.00 0.22 0.66 6.10 13

Quarterly Cash Flow Statements for Prime Medicine

This table details how cash moves in and out of Prime Medicine's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 -13 -77 -2.39 53 -39 63 64 -91 -38 18 -8.36
Net Cash From Operating Activities		 -41 -39 -44 -68 -45 -26 16 -49 -41 -35 -37
Net Cash From Continuing Operating Activities		 -41 -39 -44 -68 -45 -26 16 -49 -41 -35 -37
Net Income / (Loss) Continuing Operations		 -42 -51 -66 -46 -55 -53 -42 -52 -53 -51 -46
Consolidated Net Income / (Loss)		 -42 -51 -66 -46 -55 -53 -42 -52 -53 -51 -46
Depreciation Expense		 1.12 1.24 1.25 1.32 1.54 1.56 1.72 1.70 1.86 1.88 1.88
Amortization Expense		 -0.79 -0.92 -1.09 -0.68 -1.40 -0.87 -0.15 -0.16 -0.41 -0.57 -0.79
Non-Cash Adjustments To Reconcile Net Income		 6.79 8.93 21 -6.11 15 8.84 8.09 9.15 9.18 14 6.58
Changes in Operating Assets and Liabilities, net		 -5.56 2.29 0.95 -16 -4.88 17 49 -7.65 0.55 0.61 1.16
Net Cash From Investing Activities		 28 -38 41 -37 6.89 50 48 -48 2.77 -92 28
Net Cash From Continuing Investing Activities		 28 -38 41 -37 6.89 50 48 -48 2.77 -92 28
Purchase of Property, Plant & Equipment		 -1.98 -2.91 -1.84 -2.32 -1.90 -1.28 -1.79 -2.42 -1.57 -0.25 -0.29
Purchase of Investments		 0.01 -55 -4.41 -107 -29 -10 17 -48 -6.91 -134 -16
Sale and/or Maturity of Investments		 30 20 48 73 38 61 33 3.00 11 42 45
Net Cash From Financing Activities		 0.08 0.32 0.19 157 0.04 39 0.00 6.00 0.20 145 0.56
Net Cash From Continuing Financing Activities		 0.08 0.32 0.19 157 0.04 39 0.00 6.00 0.20 145 0.56
Issuance of Debt		 - - - 132 - - - 0.00 - 138 0.01
Issuance of Common Equity		 - - - 19 - 38 0.00 0.00 0.20 - 0.14
Other Financing Activities, net		 0.08 0.32 0.19 6.04 0.04 0.03 - 6.00 - 6.37 0.41

Annual Balance Sheets for Prime Medicine

This table presents Prime Medicine's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 302 360 194 298 343
Total Current Assets		 271 297 143 212 181
Cash & Equivalents		 185 188 42 182 63
Short-Term Investments		 68 106 80 7.97 115
Prepaid Expenses		 0.96 2.45 19 6.78 2.94
Other Current Assets		 16 0.25 2.25 15 0.67
Plant, Property, & Equipment, net		 4.93 19 23 24 21
Total Noncurrent Assets		 26 45 28 61 141
Other Noncurrent Operating Assets		 26 45 28 61 141
Total Liabilities & Shareholders' Equity		 302 360 194 298 343
Total Liabilities		 62 44 61 144 222
Total Current Liabilities		 58 27 56 38 37
Accounts Payable		 1.44 4.33 20 11 8.89
Accrued Expenses		 37 11 28 16 13
Current Deferred Revenue		 - - 0.00 7.09 7.82
Other Current Liabilities		 19 12 9.28 3.61 8.14
Total Noncurrent Liabilities		 4.31 17 4.36 106 184
Noncurrent Deferred Revenue		 - - 0.00 63 58
Other Noncurrent Operating Liabilities		 3.07 17 4.36 43 126
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -156 316 133 153 121
Total Preferred & Common Equity		 -156 316 133 153 121
Total Common Equity		 -156 316 133 153 121
Common Stock		 15 610 624 840 1,009
Retained Earnings		 -171 -293 -491 -687 -888
Accumulated Other Comprehensive Income / (Loss)		 -0.03 -0.38 -0.02 0.00 0.08

Quarterly Balance Sheets for Prime Medicine

This table presents Prime Medicine's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 281 239 311 260 333 328 279 385
Total Current Assets		 218 185 218 171 246 164 121 231
Cash & Equivalents		 121 44 94 56 118 92 54 71
Short-Term Investments		 87 121 117 107 58 52 48 142
Prepaid Expenses		 11 19 4.20 4.20 6.01 2.95 3.03 2.49
Other Current Assets		 - - 2.73 3.74 9.54 17 16 16
Plant, Property, & Equipment, net		 21 22 24 24 23 25 24 22
Total Noncurrent Assets		 42 33 70 65 63 139 134 132
Other Noncurrent Operating Assets		 42 33 70 65 63 139 134 132
Total Liabilities & Shareholders' Equity		 281 239 311 260 333 328 279 385
Total Liabilities		 41 45 68 63 143 221 218 223
Total Current Liabilities		 29 39 24 21 38 34 34 35
Accounts Payable		 5.49 14 10 4.64 5.43 10 6.38 9.35
Accrued Expenses		 9.72 14 7.61 11 19 9.19 12 11
Current Deferred Revenue		 - - - - 9.28 8.21 8.32 6.95
Other Current Liabilities		 14 11 6.75 5.22 4.48 6.86 7.26 7.71
Total Noncurrent Liabilities		 12 5.82 43 42 105 187 184 188
Noncurrent Deferred Revenue		 - - - - 63 61 60 60
Other Noncurrent Operating Liabilities		 12 5.82 43 42 43 126 124 128
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 240 194 244 197 190 107 61 162
Total Preferred & Common Equity		 240 194 244 197 190 107 61 162
Total Common Equity		 240 194 244 197 190 107 61 162
Common Stock		 615 620 781 789 834 846 853 1,004
Retained Earnings		 -375 -426 -537 -592 -645 -739 -792 -842
Accumulated Other Comprehensive Income / (Loss)		 -0.27 -0.15 -0.10 -0.07 0.02 -0.02 -0.01 0.03

Annual Metrics And Ratios for Prime Medicine

This table displays calculated financial ratios and metrics derived from Prime Medicine's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 97,208,342.00 97,324,301.00 - 180,510,658.00
DEI Adjusted Shares Outstanding		 0.00 0.00 97,208,342.00 97,324,301.00 - 180,510,658.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.46 -2.04 - -1.11
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -0.65 -59 -82 -143 -142 -146
Return On Investment Capital (ROIC_SIMPLE)		 - - - -107.73% -92.54% -120.66%
Earnings before Interest and Taxes (EBIT)		 -1.54 -166 -123 -201 -199 -205
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.50 -165 -121 -200 -196 -200
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -45 -118 -132 -93 -126
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.00 -14 22 11 -37 -57
Increase / (Decrease) in Invested Capital		 0.00 -14 36 -11 -49 -20
Book Value per Share		 $0.00 ($12.04) $3.25 $1.37 $1.17 $0.67
Tangible Book Value per Share		 $0.00 ($12.04) $3.25 $1.37 $1.17 $0.67
Total Capital		 0.00 240 316 133 153 121
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -254 -294 -122 -190 -178
Capital Expenditures (CapEx)		 0.64 4.15 16 8.72 7.29 4.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -41 -24 -35 -17 -34
Debt-free Net Working Capital (DFNWC)		 0.00 213 270 87 174 144
Net Working Capital (NWC)		 0.00 213 270 87 174 144
Net Nonoperating Expense (NNE)		 2.76 106 40 55 54 55
Net Nonoperating Obligations (NNO)		 0.00 -254 -294 -122 -190 -178
Total Depreciation and Amortization (D&A)		 0.04 1.28 1.97 1.25 3.03 5.38
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($4.19) ($2.18) ($1.65) ($1.35)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 33.89M 90.97M 118.60M 148.76M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($4.19) ($2.18) ($1.65) ($1.35)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 33.89M 90.97M 118.60M 148.76M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 97.25M 119.94M 131.16M 180.55M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.65 -59 -82 -143 -142 -146
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Prime Medicine

This table displays calculated financial ratios and metrics derived from Prime Medicine's official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 97,229,068.00 97,300,310.00 97,324,301.00 119,939,247.00 120,030,813.00 120,030,813.00 - 131,160,842.00 131,294,454.00 134,573,998.00 180,510,658.00
DEI Adjusted Shares Outstanding		 97,229,068.00 97,300,310.00 97,324,301.00 119,939,247.00 120,030,813.00 120,030,813.00 - 131,160,842.00 131,294,454.00 134,573,998.00 180,510,658.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.44 -0.52 -0.67 -0.38 -0.46 -0.44 - -0.40 -0.40 -0.38 -0.26
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -32 -36 -48 -34 -39 -38 -31 -37 -37 -38 -34
Return On Investment Capital (ROIC_SIMPLE)		 - - -35.79% -13.88% -19.82% -20.03% -20.21% -34.30% -61.39% -23.35% -28.15%
Earnings before Interest and Taxes (EBIT)		 -43 -51 -67 -46 -56 -53 -44 -53 -53 -52 -47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -43 -51 -67 -46 -56 -53 -43 -52 -52 -50 -46
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -64 -29 -37 -31 -40 -23 18 34 37 28 -15
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 32 29 11 33 34 14 -37 -37 -41 -51 -57
Increase / (Decrease) in Invested Capital		 32 -6.94 -11 -2.37 1.24 -15 -49 -70 -75 -65 -20
Book Value per Share		 $2.47 $1.99 $1.37 $2.03 $1.64 $1.58 $1.17 $0.82 $0.46 $1.20 $0.67
Tangible Book Value per Share		 $2.47 $1.99 $1.37 $2.03 $1.64 $1.58 $1.17 $0.82 $0.46 $1.20 $0.67
Total Capital		 240 194 133 244 197 190 153 107 61 162 121
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -208 -165 -122 -211 -163 -176 -190 -144 -102 -213 -178
Capital Expenditures (CapEx)		 1.98 2.91 1.84 2.32 1.90 1.28 1.79 2.42 1.57 0.25 0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -18 -20 -35 -18 -13 33 -17 -15 -15 -17 -34
Debt-free Net Working Capital (DFNWC)		 190 145 87 193 150 208 174 129 87 196 144
Net Working Capital (NWC)		 190 145 87 193 150 208 174 129 87 196 144
Net Nonoperating Expense (NNE)		 11 15 18 12 16 15 11 15 15 13 12
Net Nonoperating Obligations (NNO)		 -208 -165 -122 -211 -163 -176 -190 -144 -102 -213 -178
Total Depreciation and Amortization (D&A)		 0.33 0.32 0.16 0.64 0.13 0.69 1.57 1.54 1.45 1.31 1.09
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.47) ($0.55) ($0.72) ($0.44) ($0.46) ($0.44) ($0.31) ($0.40) ($0.41) ($0.32) ($0.22)
Adjusted Weighted Average Basic Shares Outstanding		 90.47M 91.85M 90.97M 104.47M 119.19M 119.76M 118.60M 130.88M 129.19M 160.50M 148.76M
Adjusted Diluted Earnings per Share		 ($0.47) ($0.55) ($0.72) ($0.44) ($0.46) ($0.44) ($0.31) ($0.40) ($0.41) ($0.32) ($0.22)
Adjusted Weighted Average Diluted Shares Outstanding		 90.47M 91.85M 90.97M 104.47M 119.19M 119.76M 118.60M 130.88M 129.19M 160.50M 148.76M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 97.30M 97.32M 119.94M 120.03M 120.03M 131.16M 131.16M 131.29M 134.57M 180.51M 180.55M
Normalized Net Operating Profit after Tax (NOPAT)		 -32 -36 -48 -34 -39 -38 -31 -37 -37 -38 -34
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Prime Medicine (PRME) exhibits the cash burn and funding dynamics typical of an early-stage biotech, with small quarterly revenue, heavy R&D spend, and ongoing net losses. Below is a concise, data-driven snapshot of the last four years of quarterly results, focusing on trends most relevant to retail investors.

  • Significant equity financing in Q3 2025: Prime Medicine added about $144.8 million in net cash from financing activities, reflecting a substantial capital raise to bolster liquidity.
  • Growing asset base through 2025: Total assets rose from roughly $311.4 million (Q4 2024) to about $385.0 million (Q3 2025), indicating expansion of the company's asset base.
  • Investment cash inflow in Q3 2025: Sale/maturity of investments contributed about $42.4 million in cash, supporting liquidity in that quarter.
  • Positive investing cash flow in Q4 2025: Net cash from continuing investing activities was about $28.3 million, signaling favorable investing activity that quarter.
  • Reasonable near-term liquidity in early 2025: Cash & equivalents on the balance sheet reached about $91.9 million in Q1 2025, indicating a solid cash cushion before subsequent funding rounds.
  • Revenue remains very small and fluctuates modestly around $1.1–$1.5 million per quarter (Q1 2025: $1.45M; Q2 2025: $1.12M; Q3 2025: $1.23M; Q4 2025: $0.84M).
  • R&D and SG&A drive most costs: R&D expenses run high (e.g., Q4 2025: $34.71M; Q3 2025: $43.99M) alongside substantial SG&A (e.g., Q4 2025: $14.74M), underscoring heavy upfront spend typical of pipeline development.
  • Earnings per share and shares outstanding: Negative earnings per share persist (Q4 2025 Basic EPS around -$0.22; Q3 2025 around -$0.32; Q2 2025 around -$0.41), with weighted average shares outstanding hovering around 130–181 million across 2025.
  • Ongoing quarterly losses: Net income/(loss) for 2025 consistently remained deeply negative (Q4 2025 about -$46.1M; Q3 2025 about -$50.6M; Q2 2025 about -$52.6M; Q1 2025 about -$51.9M), illustrating the high cost of early-stage development without product commercial revenue yet.
  • Negative operating cash flow in 2025: Prime Medicine reported substantial cash burn from operations (example: Q4 2025 net cash from continuing operating activities about -$37.3M; Q3 2025 about -$35.0M; Q2 2025 about -$41.4M; Q1 2025 about -$48.9M), indicating ongoing liquidity risk unless funded by external financing.
05/22/26 01:49 PM ETAI Generated. May Contain Errors.

Prime Medicine Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Prime Medicine's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Prime Medicine's net income appears to be on an upward trend, with a most recent value of -$201.14 million in 2025, rising from -$3.41 million in 2020. The previous period was -$195.88 million in 2024. Find out what analysts predict for Prime Medicine in the coming months.

Prime Medicine's total operating income in 2025 was -$208.35 million, based on the following breakdown:
  • Total Gross Profit: $4.63 million
  • Total Operating Expenses: $212.98 million

Over the last 5 years, Prime Medicine's total revenue changed from $5.21 million in 2020 to $4.63 million in 2025, a change of -11.1%.

Prime Medicine's total liabilities were at $221.87 million at the end of 2025, a 53.7% increase from 2024, and a 256.1% increase since 2021.

In the past 4 years, Prime Medicine's cash and equivalents has ranged from $41.57 million in 2023 to $187.62 million in 2022, and is currently $63.03 million as of their latest financial filing in 2025.

Over the last 5 years, Prime Medicine's book value per share changed from 0.00 in 2020 to 0.67 in 2025, a change of 67.0%.


Related Companies

Financial statements for NASDAQ:PRME last updated on 4/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
This stock has 30 days of quiet left
A small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...
Eagle Publishing | Sponsoredtc pixel
Hidden on Tesla's filing: A $12 billion "super startup"
Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...
Banyan Hill Publishing | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Trump is positioned. Elon lights the fuse.
SpaceX just revealed it holds over $1.45 billion in Bitcoin on its balance sheet. They bought at an average...
Crypto 101 Media | Sponsoredtc pixel